- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01071915
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
January 8, 2013 updated by: Ferring Pharmaceuticals
An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
Study Overview
Study Type
Interventional
Enrollment (Actual)
157
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Daegu, Korea, Republic of
- Kyoungbuk National University Hospital
-
Seongnam, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Seoul st. mary's hospital
-
Seoul, Korea, Republic of
- Korea University Hospital
-
Seoul, Korea, Republic of
- Yonsei University Health System (Sevrance Hospital)
-
Seoul, Korea, Republic of
- Yonsei University Health System Gangnam Sevrance
-
-
Gyunggi-do
-
Pyungchon, Gyunggi-do, Korea, Republic of
- Hallym University Sacred Heart Hospital
-
-
Gyungnam
-
Mulgeum-eup, Gyungnam, Korea, Republic of
- Pusan National University Yangsan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Has given written informed consent before any trial-related activity is performed.
- Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages) (except for neoadjuvant hormonal therapy/ includes patients with rising PSA after prostatectomy or radiotherapy)
- Is a male patient aged 18 years or older
- Has a screening serum testosterone level >1.5 ng/mL
- Has an ECOG (Eastern Cooperative Oncology Group) score of ≤ 2
- Has a screening PSA value of ≥2 ng/mL
- Has a life expectancy of at least 12 months
Exclusion Criteria:
- Has had previous or is currently under hormonal management of prostate cancer. However, prostatectomy or radiotherapy with curative intention, neoadjuvant/adjuvant hormonal therapy are accepted for a maximum duration of 6 months, at least 6 months prior to Screening Visit
- Is currently treated with a 5-α-reductase inhibitor
- Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
- Has a history of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema
- Has hypersensitivity towards any component of the investigational medicinal product
- A marked baseline prolongation of QT/QTcF interval
- A history of additional risk factors for Torsade de Pointes ventricular arrhythmias
- Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin
- Has a known or suspect hepatic, symptomatic biliary disease
- Has elevated serum ALT level more than the upper limit of normal or serum total bilirubin level above the upper level of normal range at the Screening Visit and confirmed with a second measurement within 21 days
- Has other clinically significant laboratory abnormalities
- Has a clinically significant disorder (other than prostate cancer) or any other condition, including alcohol or drug abuse
- Has a mental incapacity or language barriers precluding adequate understanding or co- operation
- Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial
- Has previously participated in any degarelix trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Degarelix 240/80 mg
The degarelix doses were administered into the abdominal wall every 28 days.
A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections.
The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c.
injections at 28 day intervals from day 28 to day 168.
|
The degarelix doses were administered into the abdominal wall every 28 days.
A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections.
The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c.
injections at 28 day intervals from day 28 to day 168.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196
Time Frame: Day 28 to Day 196
|
Day 28 to Day 196
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With Testosterone Level ≤0.5 ng/mL at Day 3
Time Frame: At day 3
|
At day 3
|
|
Percentage Change in Prostate-specific Antigen (PSA) From Baseline to Day 28
Time Frame: To Day 28
|
To Day 28
|
|
Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL)From Day 56 to Day 196
Time Frame: Day 56 to Day 196
|
Day 56 to Day 196
|
|
Cumulative Probability of no PSA Failure From Day 28 to Day 196
Time Frame: To Day 196
|
PSA failure was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir.
|
To Day 196
|
Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables
Time Frame: To Day 196
|
The figures present the number of participants who had markedly abnormal levels of safety laboratory variables.
Only the laboratory variables that had at least one percentage of participants in either group with abnormal value are presented, more variables were included in the study.
|
To Day 196
|
Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight
Time Frame: To Day 196
|
This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight.
The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value.
|
To Day 196
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (ACTUAL)
November 1, 2011
Study Completion (ACTUAL)
November 1, 2011
Study Registration Dates
First Submitted
February 18, 2010
First Submitted That Met QC Criteria
February 18, 2010
First Posted (ESTIMATE)
February 19, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
February 12, 2013
Last Update Submitted That Met QC Criteria
January 8, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FE200486 CS42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Degarelix 240/80 mg
-
Ferring PharmaceuticalsCompletedProstate CancerSpain, Netherlands, Belgium, Italy, France, Germany
-
Ferring PharmaceuticalsCompletedProstate CancerUnited States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
-
UCB CelltechParexel; Comac Medical; MAC Clinical Research; ARENSIA, MoldovaCompletedPsoriatic ArthritisBulgaria, Moldova, Republic of, United Kingdom
-
Ferring PharmaceuticalsCompletedLower Urinary Tract Symptoms (LUTS)United States, Canada, Belgium, Czech Republic, Italy, Poland
-
Genencell Co. Ltd.Recruiting
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Yuhan CorporationActive, not recruitingNon-Small Cell Lung CancerHungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
-
Melanoma Institute AustraliaBristol-Myers SquibbNot yet recruitingCutaneous Squamous Cell Carcinoma
-
Allist Pharmaceuticals, Inc.Not yet recruiting